ENDRA Life Sciences Inc. NDRA 深 沪
等待开盘 03-26 09:30:00 美东时间
3.75
+0.290
+8.38%
华盛通- 最 高3.90
- 今 开3.30
- 成交量 22.44万股
- 最 低 3.22
- 昨 收 3.46
- 总市值 437.40万
- 52周最高 11.96
- 市盈率 静 --
- 换手率 19.24%
- 52周最低 2.90
- 委 比 -98.15%
- 总股本 116.64万
- 历史最高 205800.00
- 量 比 14.44
- 振 幅 19.65%
- 历史最低 2.90
- 每 手 1
- 风险率 1.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ENDRA Life Sciences Says On March 19 , Reduced Number Of Employees In Order To Reduce Cash Expenditures And Extend Its Operational Runway; Expects To Incur Pre-Tax Cash Charges Of ~$51,000 Associated With Severance Payments To Former Employees
Costs Associated with Exit or Disposal Activities. On March 25, 2026, ENDRA Life Sciences Inc. (the "Company") announced that it has initiated a process to evaluate a range of strategic alternatives aimed at
03-25 21:28
Why AMTD Digital Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
AMTD Digital Inc - ADR (NYSE: HKD) jumped 24.4% in pre-market trading after reporting a 565.7% increase in FY25 revenue results to $136.1 million.
03-02 17:26
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
ENDRA Life Sciences Announces New Results From 2025 TAEUS Liver Device Feasibility Study Showing TAEUS' TAFF Measurement Closely Tracks MRI-PDFF Gold Standard At Critical LFF Thresholds Of 12-17% And 20-22%
Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoringENDRA Life Sciences Inc. (NASDAQ:NDRA)
2025-12-04 21:03
ENDRA Life Sciences Reports TAEUS Device Matches MRI Accuracy in Liver Disease Study
ENDRA Life Sciences Inc. has announced new results from a recently completed feasibility study of its TAEUS® Liver device, designed for the early detection and monitoring of steatotic liver disease (S...
2025-12-04 21:01
ENDRA Life Sciences Q3 EPS $(2.10) Misses $(1.95) Estimate
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(2.10) per share which missed the analyst consensus estimate of $(1.95) by 7.69 percent. This is a 77.99 percent increase over losses of $(9.54) per share
2025-11-17 21:20
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Leap Therapeutics (NASDAQ:LPTX) stock moved upwards by 176.6% to $1.21...
2025-11-13 01:05
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares increased by 44.9% to $2.23 ...
2025-10-15 01:06
Why Ericsson Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Shares of Telefonaktiebolaget LM Ericsson – ADR (NASDAQ:ERIC) rose sharply in p...
2025-10-14 17:45
ENDRA Life Sciences Gains Momentum With Crypto-Focused Treasury Plan
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced $4.9M in funding to launch a digital asset treasury strategy.
2025-10-14 00:24
